Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases.

Joy M.S., Frye R.F., Stubbert K., Brouwer K.R., Falk R.J., Kharasch E.D. (2010) Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases. Journal of clinical pharmacology, 50(6):714-20.

 PubMed


Urinary biomarkers for the early diagnosis of kidney cancer.

Morrissey J.J., London A.N., Luo J., Kharasch E.D. (2010) Urinary biomarkers for the early diagnosis of kidney cancer. Mayo Clinic proceedings. Mayo Clinic, 85(5):413-21.

 PubMed